Development and structural analysis of adenosine site binding tankyrase inhibitors

Teemu Haikarainen, Jo Waaler, Alexander Ignatev, Yves Nkizinkiko, Harikanth Venkannagari, Ezeogo Obaji, Stefan Krauss, Lari Lehtiö

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Tankyrases 1 and 2, the specialized members of the ARTD protein family, are druggable biotargets whose inhibition may have therapeutic potential against cancer, metabolic disease, fibrotic disease, fibrotic wound healing and HSV viral infections. We have previously identified a novel tankyrase inhibitor scaffold, JW55, and showed that it reduces mouse colon adenoma formation in vivo. Here we expanded the scaffold and profiled the selectivity of the compounds against a panel of human ARTDs. The scaffold also enables a fine modulation of selectivity towards either tankyrase 1 or tankyrase 2. In order to get insight about the binding mode of the inhibitors, we solved crystal structures of the compounds in complex with tankyrase 2. The compounds bind to the adenosine pocket of the catalytic domain and cause changes in the protein structure that are modulated by the chemical modifications of the compounds. The structural analysis allows further rational development of this compound class as a potent and selective tankyrase inhibitor.

Original languageEnglish (US)
Pages (from-to)328-333
Number of pages6
JournalBioorganic and Medicinal Chemistry Letters
Volume26
Issue number2
DOIs
StatePublished - Jan 15 2016
Externally publishedYes

Fingerprint

Tankyrases
Structural analysis
Adenosine
Binding Sites
Scaffolds
Metabolic Diseases
Chemical modification
Virus Diseases
Adenoma
Wound Healing
Catalytic Domain
Colon
Proteins
Crystal structure
Modulation

Keywords

  • ARTD
  • PARP
  • Small-molecule
  • Tankyrase
  • Tankyrase inhibitor
  • WNT inhibitor
  • WNT signaling

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Molecular Biology
  • Molecular Medicine
  • Organic Chemistry
  • Drug Discovery
  • Pharmaceutical Science

Cite this

Development and structural analysis of adenosine site binding tankyrase inhibitors. / Haikarainen, Teemu; Waaler, Jo; Ignatev, Alexander; Nkizinkiko, Yves; Venkannagari, Harikanth; Obaji, Ezeogo; Krauss, Stefan; Lehtiö, Lari.

In: Bioorganic and Medicinal Chemistry Letters, Vol. 26, No. 2, 15.01.2016, p. 328-333.

Research output: Contribution to journalArticle

Haikarainen, T, Waaler, J, Ignatev, A, Nkizinkiko, Y, Venkannagari, H, Obaji, E, Krauss, S & Lehtiö, L 2016, 'Development and structural analysis of adenosine site binding tankyrase inhibitors', Bioorganic and Medicinal Chemistry Letters, vol. 26, no. 2, pp. 328-333. https://doi.org/10.1016/j.bmcl.2015.12.018
Haikarainen, Teemu ; Waaler, Jo ; Ignatev, Alexander ; Nkizinkiko, Yves ; Venkannagari, Harikanth ; Obaji, Ezeogo ; Krauss, Stefan ; Lehtiö, Lari. / Development and structural analysis of adenosine site binding tankyrase inhibitors. In: Bioorganic and Medicinal Chemistry Letters. 2016 ; Vol. 26, No. 2. pp. 328-333.
@article{eff8356ab1ca4f28b666dadfbabd0674,
title = "Development and structural analysis of adenosine site binding tankyrase inhibitors",
abstract = "Tankyrases 1 and 2, the specialized members of the ARTD protein family, are druggable biotargets whose inhibition may have therapeutic potential against cancer, metabolic disease, fibrotic disease, fibrotic wound healing and HSV viral infections. We have previously identified a novel tankyrase inhibitor scaffold, JW55, and showed that it reduces mouse colon adenoma formation in vivo. Here we expanded the scaffold and profiled the selectivity of the compounds against a panel of human ARTDs. The scaffold also enables a fine modulation of selectivity towards either tankyrase 1 or tankyrase 2. In order to get insight about the binding mode of the inhibitors, we solved crystal structures of the compounds in complex with tankyrase 2. The compounds bind to the adenosine pocket of the catalytic domain and cause changes in the protein structure that are modulated by the chemical modifications of the compounds. The structural analysis allows further rational development of this compound class as a potent and selective tankyrase inhibitor.",
keywords = "ARTD, PARP, Small-molecule, Tankyrase, Tankyrase inhibitor, WNT inhibitor, WNT signaling",
author = "Teemu Haikarainen and Jo Waaler and Alexander Ignatev and Yves Nkizinkiko and Harikanth Venkannagari and Ezeogo Obaji and Stefan Krauss and Lari Lehti{\"o}",
year = "2016",
month = "1",
day = "15",
doi = "10.1016/j.bmcl.2015.12.018",
language = "English (US)",
volume = "26",
pages = "328--333",
journal = "Bioorganic and Medicinal Chemistry Letters",
issn = "0960-894X",
publisher = "Elsevier Limited",
number = "2",

}

TY - JOUR

T1 - Development and structural analysis of adenosine site binding tankyrase inhibitors

AU - Haikarainen, Teemu

AU - Waaler, Jo

AU - Ignatev, Alexander

AU - Nkizinkiko, Yves

AU - Venkannagari, Harikanth

AU - Obaji, Ezeogo

AU - Krauss, Stefan

AU - Lehtiö, Lari

PY - 2016/1/15

Y1 - 2016/1/15

N2 - Tankyrases 1 and 2, the specialized members of the ARTD protein family, are druggable biotargets whose inhibition may have therapeutic potential against cancer, metabolic disease, fibrotic disease, fibrotic wound healing and HSV viral infections. We have previously identified a novel tankyrase inhibitor scaffold, JW55, and showed that it reduces mouse colon adenoma formation in vivo. Here we expanded the scaffold and profiled the selectivity of the compounds against a panel of human ARTDs. The scaffold also enables a fine modulation of selectivity towards either tankyrase 1 or tankyrase 2. In order to get insight about the binding mode of the inhibitors, we solved crystal structures of the compounds in complex with tankyrase 2. The compounds bind to the adenosine pocket of the catalytic domain and cause changes in the protein structure that are modulated by the chemical modifications of the compounds. The structural analysis allows further rational development of this compound class as a potent and selective tankyrase inhibitor.

AB - Tankyrases 1 and 2, the specialized members of the ARTD protein family, are druggable biotargets whose inhibition may have therapeutic potential against cancer, metabolic disease, fibrotic disease, fibrotic wound healing and HSV viral infections. We have previously identified a novel tankyrase inhibitor scaffold, JW55, and showed that it reduces mouse colon adenoma formation in vivo. Here we expanded the scaffold and profiled the selectivity of the compounds against a panel of human ARTDs. The scaffold also enables a fine modulation of selectivity towards either tankyrase 1 or tankyrase 2. In order to get insight about the binding mode of the inhibitors, we solved crystal structures of the compounds in complex with tankyrase 2. The compounds bind to the adenosine pocket of the catalytic domain and cause changes in the protein structure that are modulated by the chemical modifications of the compounds. The structural analysis allows further rational development of this compound class as a potent and selective tankyrase inhibitor.

KW - ARTD

KW - PARP

KW - Small-molecule

KW - Tankyrase

KW - Tankyrase inhibitor

KW - WNT inhibitor

KW - WNT signaling

UR - http://www.scopus.com/inward/record.url?scp=84952896988&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952896988&partnerID=8YFLogxK

U2 - 10.1016/j.bmcl.2015.12.018

DO - 10.1016/j.bmcl.2015.12.018

M3 - Article

C2 - 26706174

AN - SCOPUS:84952896988

VL - 26

SP - 328

EP - 333

JO - Bioorganic and Medicinal Chemistry Letters

JF - Bioorganic and Medicinal Chemistry Letters

SN - 0960-894X

IS - 2

ER -